People: Mylan Inc (MYL.O)

MYL.O on Nasdaq

50.43USD
23 Oct 2014
Price Change (% chg)

-- (--)
Prev Close
$50.43
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
5,019,739
52-wk High
$57.52
52-wk Low
$36.97

Search Stocks

Summary

Name Age Since Current Position

Robert Coury

53 2012 Executive Chairman of the Board

Rajiv Malik

52 2013 President, Director

Heather Bresch

44 2012 Chief Executive Officer, Director

Rodney Piatt

61 2011 Vice Chairman of the Board, Lead Independent Director

John Sheehan

53 2010 Executive Vice President, Chief Financial Officer, Principal Financial officer

Rakesh Bamzai

2014 President - India Commercial and Emerging Markets

Anthony Mauro

41 2012 President, North America

Wendy Cameron

54 2002 Independent Director

Robert Cindrich

70 2011 Independent Director

Neil Dimick

65 2005 Independent Director

Melina Higgins

46 2013 Independent Director

Douglas Leech

59 2000 Independent Director

Joseph Maroon

73 2003 Independent Director

Mark Parrish

58 2009 Independent Director

Randall Vanderveen

63 2002 Independent Director

Kris King

Vice President

Biographies

Name Description

Robert Coury

Mr. Robert J. Coury is the Executive Chairman of the Board of Mylan Inc. Mr. Coury has served as Chairman of the Board of Mylan since May 2009, and as Executive Chairman since January 1, 2012. Prior to serving as Chairman, he served as Vice Chairman of the Board commencing in March 2002. Mr. Coury also served as Mylan’s Chief Executive Officer from September 2002 to December 31, 2011.Before joining Mylan, he was Chief Executive Officer and principal owner of Coury Consulting, L.P., a Pittsburgh, Pennsylvania corporate advisory firm that he founded in 1989.

Rajiv Malik

Mr. Rajiv Malik serves as the President, Director of Mylan Inc. Mr. Malik has served as Mylan’s President since January 1, 2012, before which he was Mylan’s Executive Vice President and Chief Operating Officer since July 2009, and Mylan’s Head of Global Technical Operations from January 2007 to July 2009. In addition to his oversight of day-to-day operations of the Company as President, Mr. Malik has been instrumental in identifying, evaluating and executing on business development opportunities, expanding and optimizing Mylan’s product portfolios and leveraging Mylan’s global research and development capabilities, among other important contributions. Previously, he served as Chief Executive Officer of Matrix Laboratories Limited (n/k/a Mylan Laboratories Limited) from July 2005 to June 2008. Prior to joining Matrix, he served as Head of Global Development and Registrations for Sandoz GmbH from September 2003 to July 2005. Prior to joining Sandoz, Mr. Malik was Head of Global Regulatory Affairs and Head of Pharma Research for Ranbaxy from October 1999 to September 2003.

Heather Bresch

Ms. Heather Bresch serves as the Chief Executive Officer, Director of Mylan Inc. Ms. Bresch has served as Mylan’s CEO since January 1, 2012. Throughout her 20-year career with Mylan, Ms. Bresch has held roles of increasing responsibility in more than 15 functional areas. Prior to becoming CEO, Ms. Bresch served as Mylan’s President from July 2009 and was responsible for the day-to-day operations of the Company. Before that, she served as Mylan’s Chief Operating Officer and Chief Integration Officer from October 2007 to July 2009. During her career, Ms. Bresch has championed initiatives aimed at improving product quality and removing barriers to patient access to medicine, including working to improve access to treatment for HIV/AIDS patients and better ensuring the quality of pharmaceutical products sold in the United States.

Rodney Piatt

Mr. Rodney L. Piatt, CPA, is Vice Chairman of the Board, Lead Independent Director of Mylan Inc. Since 1996, he has also been President and owner of Horizon Properties, a real estate and development company. Since 2003, Mr. Piatt has also served as Chief Executive Officer and Director of Lincoln Manufacturing Inc., a steel and coal manufacturing company.

John Sheehan

Mr. John D. Sheehan, C.P.A., is Executive Vice President, Chief Financial Officer, Principal Financial officer of Mylan Inc., since April 2010. Prior to joining Mylan, he served as Chief Financial Officer of Delphi Automotive LLP (“Delphi”). In addition to serving as the Chief Financial Officer for Delphi, Mr. Sheehan held several senior management positions, including chief restructuring officer, chief accounting officer and controller since joining that company in 2002. Prior to joining Delphi, Mr. Sheehan was a partner at KPMG LLP, a global professional accounting firm.

Rakesh Bamzai

Mr. Rakesh Bamzai is President - India Commercial and Emerging Markets of the company. Bamzai has more than 20 years of experience in the Indian and global biopharmaceutical industry. Prior to joining Mylan, he was president of Marketing at Biocon, where he played a key role in building the company's global biopharmaceutical business. He had overall responsibility for active pharmaceutical ingredients (API) and branded formulations and managed a team of more than 2,000 people across functional areas and geographies. Through the years, he also spearheaded many strategic partnerships that enabled the organization to gain wider global access and greater market penetration for its biopharmaceuticals business. Bamzai also led Biocon's foray into branded formulations and built many successful brands across therapies in India and Gulf Cooperation Council states. Bamzai graduated from the University of Mumbai (Department of Chemical Technology).

Anthony Mauro

Mr. Anthony Mauro serves as President, North America of Mylan Inc., since January 1, 2012. He has served as President of Mylan Pharmaceuticals Inc. since 2009. In his 15 years at Mylan, Mauro has held roles of increasing responsibility across the Company’s business units, including President of Mylan Pharmaceuticals Inc., Chief Operating Officer for Mylan Pharmaceuticals ULC in Canada, Vice President of Strategic Development, North America, and Vice President of Sales, North America.

Wendy Cameron

Ms. Wendy Cameron is an Independent Director of Mylan Inc. Ms. Cameron has served as Director and Co-Owner of Cam Land LLC, a harness racing business in Washington, Pennsylvania, since January 2003. From 1981 to 1998, she was Vice President, Divisional Sales & Governmental Affairs, Cameron Coca-Cola Bottling Company, Inc. Ms. Cameron served as Chairman of the Washington Hospital Board of Trustees and of the Washington Hospital Executive Committee until she stepped down in 2012. She had been a member of the hospital’s Board of Trustees since 1997 and a member of the Washington Hospital Foundation Board since 1993. In addition to being a business owner and having held an executive position with one of the nation’s bottlers for nearly 20 years, Ms. Cameron’s 11-year tenure on the Mylan Board has come during a period of massive growth at the Company.

Robert Cindrich

The Honorable Robert J. Cindrich is an Independent Director of Mylan Inc. Since February 2011, Mr. Cindrich has served as the President of Cindrich Consulting, LLC, a business and healthcare consulting company that advises clients on corporate governance, compliance, and business strategies. In May 2012, he joined the Board of Directors of Allscripts Healthcare Solutions, Inc., which provides healthcare information technology solutions. From 2004 through 2012, Mr. Cindrich served as a senior advisor to the Office of the President of the University of Pittsburgh Medical Center (“UPMC”), a global health enterprise. From 2004 through 2011, Mr. Cindrich was the Chief Legal Officer of UPMC. From 1994 through 2004, Mr. Cindrich served as a judge on the United States District Court for the Western District of Pennsylvania. Prior to that appointment, he was active as an attorney in both government and private practice, including positions as the Allegheny County Assistant Public Defender and Assistant District Attorney, and as the U.S. Attorney for the Western District of Pennsylvania.

Neil Dimick

Mr. Neil F. Dimick, CPA, is an Independent Director of Mylan Inc., since 2005. Currently retired, Mr. Dimick previously served as Executive Vice President and Chief Financial Officer of Amerisource Bergen Corporation, a wholesale distributor of pharmaceuticals, from 2001 to 2002. From 1992 to 2001, he was Senior Executive Vice President and Chief Financial Officer of Bergen Brunswig Corporation, a wholesale drug distributor. Prior to that experience, Mr. Dimick served as a partner with Deloitte & Touche LLP for 8 years. Mr. Dimick also serves on the Boards of Directors of WebMD Health Corp., Thoratec Corporation, and Resources Connection, Inc. Mr. Dimick served on the Board of Directors of HLTh Corporation from 2002 to 2009, at which time it was merged into WebMD Health Corp.

Melina Higgins

Ms. Melina Higgins has been appointed as an Independent Director of Mylan Inc. effective February 11, 2013. Currently retired, Ms. Higgins previously served as a Partner and Managing Director, and in other senior roles at Goldman Sachs during her nearly 20-year career at the firm. During her tenure at Goldman Sachs, Ms. Higgins served as a member of the Investment Committee of the Principal Investment Area, which oversaw and approved global private equity and private debt investments and was one of the alternative asset managers in the world. She also served as head of the Americas as well as co-chairperson of the Investment Advisory Committee for the GS Mezzanine Partners funds. She holds an M.B.A. from Harvard Business School and a B.A. from Colgate University.

Douglas Leech

Mr. Douglas J. Leech, CPA, is an Independent Director of Mylan Inc., since 2000. Mr. Leech is the founder and principal of DLJ Advisors. From 1999 to 2011, he was Founder, Chairman, President and Chief Executive Officer of Centra Bank, Inc. and Centra Financial Holdings, Inc., prior to which he was Chief Executive Officer and President of Huntington National Bank. Mr. Leech is also on the Board of Directors of United Bankshares, Inc. Mr. Leech’s public accounting, audit and professional experience has provided him both financial and business experience and leadership experience.

Joseph Maroon

Dr. Joseph C. Maroon, M.D., is an Independent Director of Mylan Inc., since 2003. Dr. Maroon is currently Professor, Heindl Scholar in Neuroscience and Vice Chairman of the Department of Neurosurgery, University of Pittsburgh Medical Center, and has held other positions at UPMC since 1998. He has also served as the team neurosurgeon for the Pittsburgh Steelers since 1981. From 1995 to 1998, Dr. Maroon was Professor and Chairman of the Department of Surgery at Allegheny General Hospital, and from 1984 to 1999 he was Professor and Chairman of the Department of Neurosurgery at Allegheny General Hospital. Dr. Maroon has earned numerous awards for his contributions to neurosurgery from various national and international neurological societies throughout his career, and patients travel from all over the world to seek his care.

Mark Parrish

Mr. Mark W. Parrish is an Independent Director of Mylan Inc., since September 1, 2009. Mr. Parrish has served as Chairman and CEO of Trident USA Health Services, a provider of mobile X-ray and laboratory services to the long-term care industry, since 2008. Since January 2013, Mr. Parrish has served on the Board of Directors of Omnicell, Inc., a company that specializes in healthcare technology. From 2001 to 2007, Mr. Parrish held management roles of increasing responsibilities with Cardinal Health Inc. and its affiliates, including Chief Executive Officer of Healthcare Supply Chain Services for Cardinal Health from 2006 to 2007. Mr. Parrish also serves as President of the International Federation of Pharmaceutical Wholesalers, an association of pharmaceutical wholesalers and pharmaceutical supply chain service companies, and senior adviser to Frazier Healthcare Ventures, a healthcare oriented growth equity firm.

Randall Vanderveen

Dr. Randall L. Vanderveen, Ph.D., R.Ph., is an Independent Director of Mylan Inc., since March 1, 2002. Dr. Vanderveen has served as Dean, John Stauffer Decanal Chair of the School of Pharmacy, University of Southern California since September 2005. From 1998 to 2005, he served as Dean of the School of Pharmacy and Graduate School of Pharmaceutical Science and Professor of Pharmacy at Duquesne University, Pittsburgh, Pennsylvania, before which he was Assistant Dean and Associate Professor at Oregon State University, in Portland, Oregon from 1988 to 1998. Dr. Vanderveen has an pharmaceutical and academic background.

Kris King

Basic Compensation

Options Compensation

Name Options Value

Robert Coury

5,099,959 50,018,530

Rajiv Malik

121,207 3,450,670

Heather Bresch

172,000 3,258,310

Rodney Piatt

0 0

John Sheehan

118,950 2,221,500

Rakesh Bamzai

0 0

Anthony Mauro

0 0

Wendy Cameron

0 0

Robert Cindrich

0 0

Neil Dimick

0 0

Melina Higgins

0 0

Douglas Leech

0 0

Joseph Maroon

0 0

Mark Parrish

0 0

Randall Vanderveen

0 0

Kris King

0 0
Search Stocks